Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.
about
IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentAdult-onset Still's disease: current challenges and future prospectsLife-threatening complications of adult-onset Still's disease.IL-6 in inflammation, immunity, and diseaseMitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray studyAdvances in understanding the pathogenesis of HLH.Tocilizumab in pediatric rheumatology: the clinical experience.Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model.IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6.Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months
P2860
Q28078134-DA31B490-BAD7-4EC6-A5FE-E0567D52C411Q28079246-40230783-32E0-4897-91A5-B35B0392ACADQ28079446-E3B54B54-E14E-46E3-B997-487C24F8090AQ33412732-099BCA00-8D3B-4D0C-8FC8-8A6CE497350BQ34248105-73C71F35-DC06-4302-882D-8D0A660084F5Q36560616-2453097E-BB9F-497D-9BD1-819453D97791Q38098232-7954D866-4113-4F46-8E3B-14ED28A07251Q38110210-2F5D57A3-8C32-4CD5-9D98-50AF7F0FE1B8Q38155126-7958F013-DB3A-4B3A-8ECF-8819E4BEF793Q38212949-E7B886D3-1277-4054-A8B9-21FF8B6FB105Q38883228-544B1519-C282-4661-B2CB-DC9DE4AA8087Q40450982-62C078AB-C5E7-4667-B9BB-1C426FFE20FFQ50496846-997B5AA4-7754-48F9-8732-B6AF1182604AQ52330721-7E7377B1-3F33-4BB2-BB1A-61B9B5673897Q53631225-074E1BB8-3442-4A98-8CC4-E27A0CEF6940Q58997590-27C8F83D-4B89-43A6-8A32-6FD064694DE2
P2860
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@ast
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@en
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@nl
type
label
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@ast
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@en
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@nl
prefLabel
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@ast
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@en
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@nl
P2093
P2860
P356
P1476
Efficacy, safety and tolerabil ...... juvenile idiopathic arthritis.
@en
P2093
Shumpei Yokota
Tadamitsu Kishimoto
Toshio Tanaka
P2860
P304
P356
10.1177/1759720X12455960
P577
2012-12-01T00:00:00Z